CEPHEID (CPHD) Shares are Up 0.36%

CEPHEID (CPHD) : Traders are bullish on CEPHEID (CPHD) as it has outperformed the S&P 500 by a wide margin of 53.91% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.2%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.36% in the last 1 week, and is up 53.08% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 3.88% and the 50-Day Moving Average is 27.26%.The 200 Day SMA reached 55.68%


CEPHEID (NASDAQ:CPHD): The stock opened in the green at $52.69 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $52.79 and a low of $52.67 for the day. The stock did not find buyers even at the lows and closed at $52.69 recording a loss of -0.08%. 1,819,329 shares exchanged hands during the trading day. The stock had closed at $52.69 in the previous days trading.

CEPHEID (CPHD) has been rated by 11 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $53 and the lowest price target forecast is $30. The average forecast of all the analysts is $44.27 and the expected standard deviation is $9.01.

Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases. Molecular testing involves various time-intensive steps, including sample preparation, DNA amplification and detection. The Companys systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to DNA amplification and detection, serves reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.